Overall, these findings link ATF3-mediated CCND1/2 activation to its SUMOylation and thereby imply this modification plays a functional role in CCND1/2 activation by ATF3 in prostate cancer PC3 and DU145 cells. The gene discussed is ATF3; the disease is prostate carcinoma.